Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
REATA PHARMACEUTICALS INC (RETA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
09/28/2023 SC 13D/A BIOGEN INC. reports a 0% stake in REATA PHARMACEUTICALS, INC.
09/28/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
09/26/2023 8-K Quarterly results
09/26/2023 SC 13D/A ROSE WILLIAM reports a 0% stake in § 240. REATA PHARMACEUTICALS, INC.
09/26/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
09/26/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/24/2023 SC 13D/A ROSE WILLIAM reports a 9.1% stake in § 240. REATA PHARMACEUTICALS, INC.
08/22/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
08/07/2023 SC 13D BIOGEN INC. reports a 23.4% stake in REATA PHARMACEUTICALS, INC.
08/01/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/31/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/31/2023 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy